Concepedia

Publication | Closed Access

Phase III Trial of Capecitabine Plus Oxaliplatin As Adjuvant Therapy for Stage III Colon Cancer: A Planned Safety Analysis in 1,864 Patients

DOI

296

Citations

19

References

2006

Year

Hans‐Joachim Schmoll, Thomas H. Cartwright, Josep Tabernero, Marek P. Nowacki, Arié Figer, Jean A. Maroun, Timothy Price, Robert Lim, Eric Van Cutsem, Young-Suk Park,
Journal of Clinical Oncology

Abstract

XELOX has a manageable tolerability profile in the adjuvant setting. Efficacy data will be available within the next 24 months.

References

YearCitations

Page 1